biostudies-literatureUnknown74(12)Fasching PA<b>Introduction:</b> The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional study for the assessment of therapy management and compliance in the routine care of postmenopausal women with invasive hormone receptor-positive breast cancer receiving letrozole. The parameters for inclusion in the study are presented and discussed here. <b>Material and Methods:</b> Between January 2008 and December 2009 a total of 5045 patients in 310 study centers were recruited to the EvaluateTM study. Inclusion criteria were hormone receptor-positive breast cancer and adjuvant treatment or metastasis. 373 patients were excluded from the analysis for variGeburtshilfe und Frauenheilkunde1137-1143https://www.ebi.ac.uk/biostudies/studies/S-EPMC4275317biostudies-literatureEvaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study.PMC4275317Harbeck NHeyl VKohls ABaake GMundhenke CWachsmann GBayer CMVollert HWSchmidt KHenschen SThomssen CDeuker JUWarm MBrucker SYJacob ABrucker CRezai MBaier BKummel SNoesslet TTesch HFasching PAde Waal JWurstlein RRezek DLandthaler RPraetz TSiebers JWGrischke EMBelleville EFischer GHein ARauh CGuggenberger MBreitbach GPFersis NWolf CKellner SKuhn TBeckmann MWKolberg HCRichter BDall PHadji PHohn AWallwiener DFehm TKrauß TJanni WfalseEvaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study.<b>Introduction:</b> The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional study for the assessment of therapy management and compliance in the routine care of postmenopausal women with invasive hormone receptor-positive breast cancer receiving letrozole. The parameters for inclusion in the study are presented and discussed here. <b>Material and Methods:</b> Between January 2008 and December 2009 a total of 5045 patients in 310 study centers were recruited to the EvaluateTM study. Inclusion criteria were hormone receptor-positive breast cancer and adjuvant treatment or metastasis. 373 patients were excluded from the analysis for vari2014-01-01T00:00:00Z2014 Dec2025-04-21T19:43:43.728Z2019-03-27T01:42:16ZS-EPMC42753172556846810.1055/s-0034-1383401